All-cause mortality after major gastrointestinal bleeding among patients receiving direct oral anticoagulants: a systematic review and meta-analysis
Open Access
- 24 May 2025
- journal article
- review article
- Published by Elsevier in Thrombosis Research
- Vol. 252, 109352
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Real world utilization of Andexanet alfa in the management of oral factor Xa inhibitor-associated gastrointestinal bleedingThe American Journal of Emergency Medicine, 2023
- Efficacy of prothrombin complex concentrate in the management of oral factor Xa inhibitors associated major bleed assessed by ISTH and ANNEXA-4 criteriaJournal of Thrombosis and Thrombolysis, 2021
- Thirty-day mortality in atrial fibrillation patients with gastrointestinal bleeding in the emergency department: differences between direct oral anticoagulant and warfarin usersInternal and Emergency Medicine, 2019
- Direct oral anticoagulant– versus vitamin K antagonist–related gastrointestinal bleeding: Insights from a nationwide cohortAmerican Heart Journal, 2019
- Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral AnticoagulantsThe American Journal of Medicine, 2018
- Management of Factor Xa inhibitor-associated life-threatening major hemorrhage: A retrospective multi-center analysisThe American Journal of Emergency Medicine, 2018
- Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-lifeInternational Journal of Cardiology, 2017
- Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated With Dabigatran or Rivaroxaban for Nonvalvular Atrial FibrillationJAMA Internal Medicine, 2016
- Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial FibrillationJACC, 2013
- Death and Disability from Warfarin-Associated Intracranial and Extracranial HemorrhagesThe American Journal of Medicine, 2007